{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:01:02Z","timestamp":1791223262046,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,3,23]],"date-time":"2008-03-23T00:00:00Z","timestamp":1206230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To analyse the impact of combined antiretroviral treatment (cART) on survival with AIDS, according to the nature of the first AIDS\u2010defining clinical illness (ADI); to examine trends in AIDS\u2010defining causes (ADC) and non\u2010AIDS\u2010defining causes (non\u2010ADC) of death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From the French Hospital Database on HIV, we studied trends in the nature of the first ADI and subsequent survival in France during three calendar periods: the pre\u2010cART period (1993\u20131995; 8027 patients), the early cART period (1998\u20132000; 3504 patients) and the late cART period (2001\u20132003; 2936 patients).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The three most frequent initial ADIs were <jats:italic>Pneumocystis carinii<\/jats:italic> (<jats:italic>jirovecii<\/jats:italic>) <jats:italic>pneumonia<\/jats:italic> (PCP) (15.6%), oesophageal candidiasis (14.3%) and Kaposi's sarcoma (13.9%) in the pre\u2010cART period. In the late cART period, the most frequent ADIs were tuberculosis (22.7%), PCP (19.1%) and oesophageal candidiasis (16.2%). The risk of death after a first ADI fell significantly after the arrival of cART. Lower declines were observed for progressive multifocal leukoencephalopathy, lymphoma and <jats:italic>Mycobacterium avium<\/jats:italic> complex infection. After an ADI, the 3\u2010year risk of death from an ADC fell fivefold between the pre\u2010cART and late cART periods (39%<jats:italic>vs<\/jats:italic>. 8%), and fell twofold for non\u2010ADCs (17%<jats:italic>vs<\/jats:italic>. 9%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The relative frequencies of initial ADI have changed since the advent of cART. Tuberculosis is now the most frequent initial ADI in France; this is probably the result of the increasing proportion of migrants from sub\u2010Saharan Africa. After a first ADI, cART has a major impact on ADCs and a smaller impact on deaths from other causes. The risk of death from AIDS and from other causes is now similar.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2008.00554.x","type":"journal-article","created":{"date-parts":[[2008,3,24]],"date-time":"2008-03-24T04:01:36Z","timestamp":1206331296000},"page":"246-256","source":"Crossref","is-referenced-by-count":60,"title":["Causes of the first AIDS\u2010defining illness and subsequent survival before and after the advent of combined antiretroviral therapy<sup>*<\/sup>"],"prefix":"10.1111","volume":"9","author":[{"given":"S","family":"Grabar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Lanoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Mary\u2010Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bentata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Mahamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Rabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Costagliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Clinical Epidemiology Group of the French Hospital Database on HIV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,23]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","author":"Centers for Disease Control and Prevention.","year":"1992","journal-title":"Morb Mortal Wkly Rep"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/26.2.400"},{"key":"e_1_2_7_4_2","first-page":"1194","article-title":"Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland","volume":"315","author":"Egger M","year":"1997","journal-title":"prospective multicentre study"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03201-2"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200205010-00015"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.6.450"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.17.1497"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2001.0810"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.10.1308"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200012150-00011"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200204010-00010"},{"key":"e_1_2_7_14_2","first-page":"2009","article-title":"Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy","volume":"19","author":"Schneider MF","year":"2005","journal-title":"1984\u20132004"},{"key":"e_1_2_7_15_2","first-page":"22","article-title":"Decline in the AIDS and death rates in the EuroSIDA Study","volume":"362","author":"Mocroft A","year":"2003","journal-title":"an observational study"},{"key":"e_1_2_7_16_2","first-page":"121","article-title":"Causes of death among human immunodeficiency virus (HIV)\u2010infected adults in the era of potent antiretroviral therapy","volume":"34","author":"Lewden C","year":"2005","journal-title":"emerging role of hepatitis and cancers, persistent role of AIDS"},{"key":"e_1_2_7_17_2","first-page":"194","article-title":"Comparisons of causes of death and mortality rates among HIV\u2010infected persons","volume":"41","author":"Crum NF","year":"2006","journal-title":"analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00271.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01169-5"},{"key":"e_1_2_7_20_2","first-page":"27","article-title":"Mortality in the highly active antiretroviral therapy era","volume":"43","author":"Palella FJ","year":"2006","journal-title":"changing causes of death and disease in the HIV outpatient study"},{"key":"e_1_2_7_21_2","first-page":"397","article-title":"Causes of death among persons with AIDS in the era of highly active antiretroviral therapy","volume":"145","author":"Sackoff JE","year":"2006","journal-title":"New York City"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-6-200009190-00007"},{"key":"e_1_2_7_23_2","first-page":"168","article-title":"Record\u2010linkage between two anonymous databases for a capture\u2013recapture estimation of underreporting of AIDS cases","volume":"29","author":"Bernillon P","year":"2000","journal-title":"France 1990\u20131993. The Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodeficience Humaine"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602102"},{"key":"e_1_2_7_26_2","first-page":"536","article-title":"Improving estimates of event incidence over time in populations exposed to other events","volume":"56","author":"Alberti C","year":"2003","journal-title":"application to three large databases"},{"key":"e_1_2_7_27_2","first-page":"1","article-title":"Comment vit\u2010on en France avec le VIH\/sida? [How do we live in France with HIV\/AIDS?]","volume":"406","author":"Lert F","year":"2004","journal-title":"Pop Soc"},{"key":"e_1_2_7_28_2","unstructured":"LanoyE LewdenC LievreLet al. What happens to patients from the French Hospital Database on HIV lost to follow\u2010up and consequences on mortality estimates.European AIDS Conference. Madrid Spain October 2007 [Abstract P184\/10]."},{"key":"e_1_2_7_29_2","first-page":"2237","article-title":"Migrants from Sub\u2010Saharan Africa in the Swiss HIV Cohort Study","volume":"17","author":"Staehelin C","year":"2003","journal-title":"access to antiretroviral therapy, disease progression and survival"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2339"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/322622"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-4-200208200-00008"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101183440302"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-2-200701160-00003"},{"key":"e_1_2_7_35_2","first-page":"624","article-title":"Trends in AIDS and mortality in HIV\u2010infected subjects with hemophilia from 1985 to 2003","volume":"41","author":"Del Amo J","year":"2006","journal-title":"the competing risks for death between AIDS and liver disease"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000216375.99560.a2"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0755-4982(04)98968-3"},{"key":"e_1_2_7_38_2","unstructured":"MocroftA. Clinical endpoints for randomized clinical trials: all AIDS\u2010defining conditions are not created equal.14th Conference on Retroviruses and Opportunistic Infections. Los Angeles CA February 2007 [Abstract 80]."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2008.00554.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2008.00554.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:48:19Z","timestamp":1696877299000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2008.00554.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,23]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1468-1293.2008.00554.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2008.00554.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,23]]}}}